Applications

1811 – Testing for MET overexpression and amplification in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) to determine eligibility for treatment with PBS subsidised savolitinib in combination with osimertinib

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type New application
  • Pre-PASC consultation Open
  • Pre-MSAC consultation -
  • Outcome Pending

Application details

Applicant

AstraZeneca Pty Ltd

Reason for application

New Medicare Benefits Schedule item.

Service or technology in this application

Patients with non-small cell lung cancer (NSCLC) often experience cancer progression due to resistance mechanisms. A common cause of this resistance is changes to the MET proto-oncogene, receptor tyrosine kinase (MET) protein, which can lead to tumour growth and metastases. To detect these changes, two main methods are used: immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). IHC uses a special stain to visualize the MET receptor on tumour cells, while FISH uses a fluorescent marker to count MET gene copies in each cell. These tests help identify which patients might be eligible for a potential new PBS-subsidised treatment, savolitinib in combination with osimertinib.

Type: Investigative

Medical condition this application addresses

NSCLC is a specific subtype of lung cancer that can be further classified according to the presence of different types of genetic changes within a cell’s DNA that affect tumour growth and invasiveness. Patients with advanced NSCLC may have a targetable genomic changes and biomarker testing is indicated to detect actionable changes and inform appropriate treatment.

Application documents

Application summary

PICO Set

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Consultation survey and deadlines

The following consultation deadlines apply:

  • Pre-PASC consultation deadline: Friday 7 November 2025 11:59 pm AEDT  
  • Pre-MSAC consultation deadline: 

Input received after the pre-PASC deadline will be considered by MSAC.

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

Meetings to consider this application

This application will be considered at the following meetings:

  • PASC meeting: 11 to 12 December 2025
  • ESC meeting:
  • MSAC meeting: 

Find out more about our meetings.

Outcome details

The outcome of this application is pending.

More information

Find out more about: